<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394913</url>
  </required_header>
  <id_info>
    <org_study_id>ETAEMS0411</org_study_id>
    <nct_id>NCT01394913</nct_id>
  </id_info>
  <brief_title>Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>A Prospective, Double-blind, Randomized Study to Compare Efficacy of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a comparison of safety and efficacy of two etanercept regimens (REUMATOCEPT®&#xD;
      versus ENBREL®) for treatment of Rheumatoid Arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      • Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
        -  Experiment duration: 30 weeks&#xD;
&#xD;
        -  9 visits (days 0, 14, 42, 70, 98, 126, 154, 182, 210)&#xD;
&#xD;
        -  Health Assessment Questionnaire (HAQ) evaluation&#xD;
&#xD;
        -  Disease Activity Score (DAS28) evaluation&#xD;
&#xD;
        -  Clinical Disease Activity Index (CDAI) evaluation&#xD;
&#xD;
        -  American College of Rheumatology criteria (ACR) evaluation&#xD;
&#xD;
        -  Visual Activity Schedule(VAS) evaluation&#xD;
&#xD;
        -  Adverse events evaluation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision&#xD;
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>day 1 to day 210</time_frame>
    <description>Health Assessment Questionnaire (HAQ)&#xD;
Disease Activity Score (DAS28)&#xD;
Clinical Disease Activity Index (CDAI)&#xD;
American College of Rheumatology criteria (ACR)&#xD;
Visual Activity Schedule(VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>day 1 to day 210</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Reumatocept 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg each week for 30 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel 25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg each week for 30 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reumatocept (etanercept)</intervention_name>
    <description>50mg each week for 30 weeks</description>
    <arm_group_label>Reumatocept 25mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel (etanercept)</intervention_name>
    <description>50mg each week for 30 weeks</description>
    <arm_group_label>Enbrel 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be able to understand the study procedures agree to participate and give&#xD;
             written consent.&#xD;
&#xD;
          2. Patients with clinical diagnosis of moderate to severe rheumatoid arthritis according&#xD;
             to American College of Rheumatology (ACR) criteria;&#xD;
&#xD;
          3. Patients with at least 6 swollen joints&#xD;
&#xD;
          4. Patients with partial response in treatment with methotrexate for 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy and Lactation&#xD;
&#xD;
          2. Patients with uncontrolled hypertension&#xD;
&#xD;
          3. Patients with other rheumatic disease such as Sjogren syndrome, systemic lupus&#xD;
             erythematosus or spondyloarthritis&#xD;
&#xD;
          4. Non-steroidal anti-inflammatory drug in the last 4 weeks&#xD;
&#xD;
          5. Any pathology or past medical condition that can interfere with this protocol&#xD;
&#xD;
          6. Patients with immunodeficiency and/or immunosuppressive disease;&#xD;
&#xD;
          7. Other conditions deemed reasonable by the medical investigator as to the&#xD;
             disqualification of the individual from study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Pinho, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associação de Assitência à Criança Deficiente</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04038004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

